Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Open trial of risperidone in 24 young children with pervasive developmental disorders
Autore:
Masi, G; Cosenza, A; Mucci, M; Brovedani, P;
Indirizzi:
Univ Pisa, Div Child Neurol & Psychiat, I-56018 Pisa, Italy Univ Pisa Pisa Italy I-56018 hild Neurol & Psychiat, I-56018 Pisa, Italy IRCCS Stella Maris, Pisa, Italy IRCCS Stella Maris Pisa ItalyIRCCS Stella Maris, Pisa, Italy
Titolo Testata:
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY
fascicolo: 10, volume: 40, anno: 2001,
pagine: 1206 - 1214
SICI:
0890-8567(200110)40:10<1206:OTORI2>2.0.ZU;2-2
Fonte:
ISI
Lingua:
ENG
Soggetto:
AUTISM RATING-SCALE; CHILDHOOD AUTISM; PEDIATRIC PSYCHOPHARMACOLOGY; INFANTILE-AUTISM; ADOLESCENTS; HALOPERIDOL; DIAGNOSIS; SYMPTOMS; EFFICACY; NETWORK;
Keywords:
autistic disorder; risperidone; children;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Citazioni:
42
Recensione:
Indirizzi per estratti:
Indirizzo: Masi, G Univ Pisa, Div Child Neurol & Psychiat, Via dei Giacinti 2, I-56018 Pisa, Italy Univ Pisa Via dei Giacinti 2 Pisa Italy I-56018 56018 Pisa, Italy
Citazione:
G. Masi et al., "Open trial of risperidone in 24 young children with pervasive developmental disorders", J AM A CHIL, 40(10), 2001, pp. 1206-1214

Abstract

Objective: To describe tolerability and efficacy of risperidone in very young children with pervasive developmental disorders, Method: Twenty-four children aged 3.6 to 6.6 years (mean 4.6 years +/- 8 months) enrolled during 1999 and 2000 participated in a 16-week open-label trial with risperidone monotherapy. Outcome measures included the Children's Psychiatric Rating Scale (CPRS), Childhood Autism Rating Scale (CARS), Clinical Global Impression-Improvement (CGI-I), and Children's Global Assessment Scale (C-GAS). Results: Two subjects did not complete the trial because of side effects. The optimal dose was 0.5 mg/day. After the treatment a 21 % improvement in CPRS and a 14% improvement in CARS total scores was found. Items related to behavioral control (hyperactivity, fidgetiness, rhythmic motions) and affect regulation (lability of affect, angry affect) improved more than 25%. Based onimprovement of at least 25% on the CPRS and a score of 1 or 2 on the CGI-I, eight subjects were considered responders. Functional impairment (C-GAS) improved more than 25%. Thirteen subjects (54%) were free of any side effects; in the other participants risperidone was well tolerated, Only three subjects had a weight gain greater than 10%. Conclusions: Low-dose risperidone may positively affect symptoms in young autistic children, improving disruptive/hyperactive behavior and affective dysregulation. Further controlledstudies in this age group are warranted.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/01/20 alle ore 10:56:46